Slovenia Pharmaceuticals & Healthcare Q4 2006

Published by: Business Monitor International

Published: Oct. 1, 2006 - 62 Pages

Table of Contents

Chapter 1 - Executive Summary

Slovenia Pharmaceuticals & Healthcare Industry SWOT

Slovenia Political SWOT

Slovenia Economic SWOT

Slovenia Business Environment SWOT

Chapter 2 - Slovenia: Business Environment Ranking

Table: Central & Eastern Europe Pharmaceutical Business

Environment Ranking

Business Environment Ranking

Economics - Long-Term Risk

Politics - Long-Term Risk

Regulatory Barriers

Domestic Sector Threat

Market Growth Potential

Market Size Ranking

Chapter 3 - Slovenia: Market Summary

Chapter 4 - Regulatory Regime

Intellectual Property Developments

Patent Disputes

Pricing System

Reimbursement Policies

Chapter 5 - Industry Developments

Healthcare Sector

Table: Leading Causes of Death in Slovenia

Pharmaceutical Industry

Chapter 6 - Industry Forecast Scenario

Overall Market Forecast

Table: Slovenia Drug Market Indicators

Key Growth Factors - Industry

Table: Health Expenditure Indicators

Key Growth Factors - Macroeconomic

Table: GDP, Output And Population

Prescription Market Forecast

Table: Prescription Drug Market Indicators

Table: OTC Market Indicators

Generics and Branded Markets Forecast

Table: Slovenia Generics and Branded Market Forecast Indicators

Export/Import Forecasts

Table: Export/Import Trend

Table - Hospital Data Trends

Key Risks to BMI’s Forecast Scenario

Chapter 7 - Country Snapshot: Slovenia Demographic Data

Section 1: Population:

Slovenia Pharmaceuticals & Healthcare Report Q3 2006

Table: Demographic Indicators (2005)

Table: Rural/Urban Breakdown

Section 2: Education & Healthcare

Table: Education

Table: Healthcare: Vital Statistics

Table: Healthcare: Expenditure

Section 3: Labour Market And Spending Power

Table: Employment Indicators

Table: Consumption and Stratification

Table: Wages per year

Chapter 8 - Competitive Landscape

Multinational Company Profiles

Pfizer

GlaxoSmithKline

Novartis

Sanofi-Aventis

Merck & Co

Chapter 9 - Indigenous Company Profiles

Krka

Lek

Chapter 10 - BMI Forecast Modelling

How We Generate Our Industry Forecasts

Pharmaceutical Industry

Sources

Chapter 11 - Appendix: Regional Demographic Data

Wages (ave. labour force per annum), US$ PPP

Population

Household Spending Per Capita, US$

Private Consumption Per Capita, US$ PPP

Market Size, GDP, US$bn

Abstract

Slovenia boasts a small but advanced pharmaceutical market, which holds modest longer-term potential. Main drivers of future growth include the ageing population and rising demand for novel treatments, as well as local investment by foreign companies. However, the market is poised for period of uncertainty as the country adopts the euro in January 2007 - primarily as result of overstocking in late 2006 in anticipation of higher prices - although the euro will boost foreign direct investment (FDI) and imports. Additionally, problems with intellectual property (IP) and pricing and reimbursement regimes will continue to cause concern for foreign research-based manufacturers.

The pharmaceutical market was valued at US$517mn in 2005, which equates to annual per capita expenditure of over US$200. BMI expects the value of the market to reach US$718mn by 2010. Prescription medicines will remain dominant, at around 90% of the total. Over-the-counter (OTC) segment will benefit from cost-containment pressures, as well as improvements in patient purchasing power and possible deregulation of the retail pharmacy market. Generic drugs will continue to receive government support, as the authorities protect the local industry, although therapeutic advances and rising healthcare expectations will promote the branded sector growth.

In regional terms, BMI's adjusted Business Environment Rankings for Central and Eastern Europe (CEE) place Slovenia in the tenth place. The country lags behind a number of its neighbours, not just the more advanced markets such as the Czech Republic, but also its faster-growing immediate neighbours, such as Bulgaria. Factors include the strong local manufacturing sector, market saturation and certain deficiencies within the country's regulatory infrastructure, and in particular reimbursement policy.

Slovenia's pharmaceutical demand is almost met by domestic production and imports on an almost equal basis in value terms. Local generic leaders Krka and Lek dominate the landscape, with multinationals mostly involved through imported medicines rather than local production. CEE markets in general and, more specifically, Eastern European, South-Eastern European and the Commonwealth of Independent States (CIS) markets are the key destinations for Slovenian export production. Given the relatively small size of the Slovenian market and its comparatively mature level of development, the majority of Slovenia's pharmaceutical output will mostly continue to be destined for export.

Key Benefits of Report

Rely On Our Independent 5-Year Forecasts As A Benchmark
to test other views - a key input for successful budgetary and strategic business planning.

Target Business Opportunities & Risks
through our reviews of latest industry trends, regulatory changes, and major deals, projects and investments

Exploit Latest Competitive Intelligence & Company SWOTS
on your competitors and peers through company rankings by sales, market share and ownership structure - includes multinational and national companies.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.